Skip to main content
FENNEC PHARMACEUTICALS INC. logo

FENNEC PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · FENC ISIN · CA31447P1009 LEI · 5299003IE70ITO2CBM73 US Manufacturing
Filings indexed 762 across all filing types
Latest filing 2019-02-14 Major Shareholding Noti…
Country CA Canada
Listing US FENC

About FENNEC PHARMACEUTICALS INC.

https://fennecpharma.com/

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of its proprietary product, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate designed to reduce the risk of ototoxicity (permanent hearing loss) associated with cisplatin chemotherapy. The product is specifically indicated for pediatric patients with localized, non-metastatic solid tumors. The company's core mission is to address this significant unmet medical need in pediatric oncology, preventing lifelong hearing loss in children undergoing cancer treatment.

Recent filings

Filing Released Lang Actions
FEBRUARY 14, 2019
Major Shareholding Notification
2019-02-14 English
FENNEC PHARMACEUTICALS INC.
Major Shareholding Notification
2019-02-14 English
FORM 8-K
Regulatory Filings
2019-02-04 English
FORM 10-Q
Interim / Quarterly Report Q3 2018
2018-11-13 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-09-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-08-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.